new_0222_0456|LABP|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|sga_expense|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|short_interest|forward_pe_ratio|forward_pe_ratio_1y|forward_ps_ratio|forward_ps_ratio_1y|quarterly_eps_estimates|quarterly_sales_estimates|quarterly_eps_surprise|quarterly_sales_surprise|quarterly_eps_actual|quarterly_sales_actual|sales_est_0y|sales_est_1y|price_target|consensus_recommendation|price_target_num_est|eps_est_0y|eps_est_1y|r_and_d_expense|reconciled_depreciation|interest_expense_non_operating|land_and_improvements|buildings_and_improvements|other_properties|machinery_furniture_equipment|price_next_month|price_second_month
new_0222_0456|LABP|1|Landos Biopharma Inc Total Current Assets (Quarterly) (USD)|Landos Biopharma Inc Cash and Short Term Investments (Quarterly) (USD)|Landos Biopharma Inc Inventories (Quarterly) (USD)|Landos Biopharma Inc Net PP&E (Quarterly) (USD)|Landos Biopharma Inc Goodwill and Intangibles (Quarterly) (USD)|Landos Biopharma Inc Total Liabilities (Quarterly) (USD)|Landos Biopharma Inc Total Current Liabilities (Quarterly) (USD)|Landos Biopharma Inc Total Long Term Liabilities (Quarterly) (USD)|Landos Biopharma Inc Total Deposits (Quarterly) (USD)|Landos Biopharma Inc Book Value (Quarterly) (USD)|Landos Biopharma Inc Retained Earnings (Quarterly) (USD)|Landos Biopharma Inc Treasury Stock (Quarterly) (USD)|Landos Biopharma Inc EV to Revenues|Landos Biopharma Inc EV to Earnings|Landos Biopharma Inc EV to Free Cash Flow|Landos Biopharma Inc EV to Assets (Quarterly)|Landos Biopharma Inc PS Ratio|Landos Biopharma Inc PE Ratio|Landos Biopharma Inc Price to Book Value|Landos Biopharma Inc PEG Ratio|Landos Biopharma Inc Debt to Equity Ratio|Landos Biopharma Inc Dividend Yield|Landos Biopharma Inc Shareholder Yield (TTM)|Landos Biopharma Inc Percent of Shares Outstanding Short|Landos Biopharma Inc Total Receivables (Quarterly) (USD)|Landos Biopharma Inc Total Payables (Quarterly) (USD)|Landos Biopharma Inc Total Capital Stock (Quarterly) (USD)|Landos Biopharma Inc Return on Invested Capital|Landos Biopharma Inc Quality Ratio Score|Landos Biopharma Inc Momentum Score|Landos Biopharma Inc Beta (1Y)|Landos Biopharma Inc Sustainable Growth Rate (TTM)|Landos Biopharma Inc Institutional Investor Ownership Percentage|Landos Biopharma Inc Average Diluted Shares Outstanding (Quarterly)|Landos Biopharma Inc Total Employees (Annual)|Landos Biopharma Inc EPS Diluted (Quarterly) (USD)|Landos Biopharma Inc SG&A Expense (Quarterly) (USD)|Landos Biopharma Inc Shares Outstanding|Landos Biopharma Inc Repurchase of Capital Stock (Quarterly) (USD)|Landos Biopharma Inc Ordinary Shares Number (Quarterly)|Landos Biopharma Inc Payout Ratio|Landos Biopharma Inc Quick Ratio (Quarterly)|Landos Biopharma Inc Normalized Diluted EPS (Quarterly) (USD)|Landos Biopharma Inc Stock Buybacks (Quarterly) (USD)|Landos Biopharma Inc Effective Tax Rate (TTM)|Landos Biopharma Inc Return on Equity|Landos Biopharma Inc Net Income (TTM) (USD)|Landos Biopharma Inc Revenue (TTM) (USD)|Landos Biopharma Inc Dividend Per Share (Quarterly) (USD)|Landos Biopharma Inc Revenue (Quarterly) (USD)|Landos Biopharma Inc Gross Profit (Quarterly) (USD)|Landos Biopharma Inc Pre-Tax Income (Quarterly) (USD)|Landos Biopharma Inc Net Income (Quarterly) (USD)|Landos Biopharma Inc Net Interest Income (Quarterly) (USD)|Landos Biopharma Inc Price (USD)|Landos Biopharma Inc Total Return Price (USD)|Landos Biopharma Inc Enterprise Value (USD)|Landos Biopharma Inc 30-Day Average Daily Volume|Landos Biopharma Inc 1 Year Price Returns (Daily)|Landos Biopharma Inc Short Interest|Landos Biopharma Inc PE Ratio (Forward)|Landos Biopharma Inc PE Ratio (Forward 1y)|Landos Biopharma Inc PS Ratio (Forward)|Landos Biopharma Inc PS Ratio (Forward 1y)|Landos Biopharma Inc Quarterly EPS Estimates (USD)|Landos Biopharma Inc Quarterly Revenue Estimates (USD)|Landos Biopharma Inc Quarterly EPS Surprise|Landos Biopharma Inc Quarterly Revenue Surprise|Landos Biopharma Inc Quarterly Actual EPS (USD)|Landos Biopharma Inc Quarterly Actual Revenue (USD)|Landos Biopharma Inc Revenue Estimates for Current Fiscal Year (USD)|Landos Biopharma Inc Revenue Estimates for Next Fiscal Year (USD)|Landos Biopharma Inc Price Target (USD)|Landos Biopharma Inc Consensus Recommendation|Landos Biopharma Inc Price Target Num Estimates|Landos Biopharma Inc EPS Estimates for Current Fiscal Year (USD)|Landos Biopharma Inc EPS Estimates for Next Fiscal Year (USD)|Landos Biopharma Inc Research and Development Expense (Quarterly) (USD)|Landos Biopharma Inc Reconciled Depreciation (Quarterly) (USD)|Landos Biopharma Inc Non-Operating Interest Expense (Quarterly) (USD)|Landos Biopharma Inc Land and Improvements (Quarterly) (USD)|Landos Biopharma Inc Buildings and Improvements (Quarterly) (USD)|Landos Biopharma Inc Other Properties (Quarterly) (USD)|Landos Biopharma Inc Machine, Furniture & Equipment (Quarterly) (USD)||
new_0222_0456|LABP|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_per_share_metric|percent_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_USD_metric|figure_whole_USD_price|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric||
new_0222_0456|LABP|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|monthly|quarterly|quarterly|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|monthly|monthly|monthly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0456|LABP|5|127.8|127.8||127.8||127.8|127.8|127.8||127.8|127.8||||1.44106463878|92|||1.44|||1.44106463878||15.347826087|127.8|127.8|127.8||||||30.6363636364|91.2857142857|92|91.2857142857|91.2857142857|31.7777777778||127.8|||91.2857142857|91.25|||91.25|||||91.2857142857|91.2857142857|91.2857142857|1.44106463878|1.44106463878|1.44106463878|1.44017094017|1.4|15.347826087|||1.44106463878|1.44106463878|91.25|91.25|91||91|91|30.5833333333|33.8888888889|25.5833333333|11.3703703704|25.5833333333|33.3636363636|27.5|91.2857142857|91.2857142857|91.2857142857|||183|183||
new_0222_0456|LABP|6|5|5||5||5|5|5||5|5||||263|1|||225|||263||23|5|5|5||||||11|7|1|7|7|9||5|||7|4|||4|||||7|7|7|263|263|263|234|10|23|||263|263|8|8|3||3|3|12|9|12|27|12|11|10|7|7|7|||2|2||
new_0222_0456|LABP|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0456|LABP|201912|50.11|49.965||0.359||76.063|3.026|73.037||-25.583|-25.585||||||||||||||0.001|2.048|0.063|||||||32.618||-0.1075|0.381|||39.1632|||-0.1097|||||||||-3.508|-3.508|0.16||||||||||||||||||||||||3.357|0.028||||0.463|0.108||
new_0222_0456|LABP|202003||||||||||||||||||||||||||||||||||32.618||-0.1777|1.08||||||-0.1709|||||||||-5.796|-5.796|-0.001||||||||||||||||||||||||4.69|0.029|0.001||||||
new_0222_0456|LABP|202006||||||||||||||||||||||||||||||||||32.618||-0.1465|1.365||||||-0.1518|||||||||-4.777|-4.777|0.136||||||||||||||||||||||||3.723|0.037|||||||
new_0222_0456|LABP|202009|35.577|35.331||0.348||80.996|7.959|73.037||-44.234|-44.388||||||||||||||0.113|6.652|0.067|||||||32.618|33|-0.2523|1.453|||39.1632|||-0.2549||||-22.311|||||-8.23|-8.23|0.105||||||||||||||||||||||||6.966|0.036||||0.468|0.189||
new_0222_0456|LABP|202012|29.888|28.134||0.444||84.347|11.034|73.313||-54.015|-55.729||||-21.5956|||||||||1.5206|0.154|8.606|0.071||||||47.3561|39.1632|33|-0.2896|1.44|39.1632||39.1632|||-0.2906||||-30.144|||||-11.341|-11.341|0.018|13.48|13.48|499.7859|||595510|||29.3289|158.3761|-0.5||-72||-0.86|||||||-2.26||9.959|0.035||||0.468|0.194||
new_0222_0456|LABP|202103|109.745|106.358||0.465||9.031|8.819|0.212||101.179|-65.547||||-8.5722||||3.7944|||||2.2767|0.001|8.2|0.399|||||||26.0705||-0.38|2.646|39.8667||39.8667|||-0.3807|-90.506|||-34.166|||||-9.818|-9.818||9.63|9.63|277.5583|211197.4667||907658|||21.3287|115.175|-0.3336||-13.8952||-0.38||9|2.5|25.5|1.75|4|-1.89|-2.5187|7.254|0.043||||||11.02|10.98
new_0222_0456|LABP|202106|117.727|115.127||0.564||12.679|12.53|0.149||105.612|-61.45||||-20.048|2.9227|||4.3637|||||1.3305|0.002|10.685|0.399|||||||34.3848||0.12|2.596|39.9009||39.9009||9.1883|0.1201||||-25.292|||18||4.097|4.097|0.179|11.55|11.55|345.7284|50933.0667||530866|||25.6031|138.2568|-0.3741|9|132.0804|100|0.12|18|9||26|1.75|4|-1.8758|-2.2192|11.522|0.05||||||10.98|13.28
new_0222_0456|LABP|202109|104.318|102.67||0.78||11.18|11.095|0.085||93.918|-74.054||||-20.1196|4.0756|||6.2265|||||0.7794|0.003|10.114|0.401||||||59.4938|39.9621||-0.32|3.059|40.0532||40.0532|||-0.3197||||-29.666|||||-12.604|-12.604|-0.191|14.6|14.6|482.1067|49814.6667||312164|||32.4876|175.4332|-0.3912||18.2109||-0.32||15|3.3333|32.8333|1.6667|6|-1.0974|-2.3206|9.344|0.048|0.191|||||13.46|7.23
new_0222_0456|LABP|202112|||||||||||||||-3.7752||||2.0564|||||0.369|||||||||59.9013||||||||||||||||||||||4.8|4.8|90.4614|116930.1667|-85.8444|148481|||57.9395|32.1886|-0.2998||||||18|3.3333|29.9|2|5|-0.847|-1.51||||||||3.43|2.02
new_0222_0456|LABP|202203|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.3667|||||||||||||||||||||
new_0222_0456|LABP|202206|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.4|||||||||||||||||||||
new_0222_0456|LABP|202209|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.32|3.3333||||||||||||||||||||
new_0222_0456|LABP|202212|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.4333|||||||||||||||||||||